Walder C E, Thomas G R, Thiemermann C, Vane J R
William Harvey Research Institute, St. Bartholomew's Hospital Medical College, London, England.
J Cardiovasc Pharmacol. 1989;13 Suppl 5:S93-7; discussion S102. doi: 10.1097/00005344-198900135-00023.
The pressor effects of porcine (ET-1) and rat (ET-3) endothelins were studied in the pithed rat along with the actions of cyclo-oxygenase inhibitors upon these responses. Indomethacin (15 mumol/kg i.v.) when given prior to endothelin had no effect on the pressor responses to ET-1 or ET-3. However, when indomethacin or piroxicam was administered between two doses of ET-1 or ET-3, the second response was significantly potentiated. This potentiation was abolished when the adrenal glands were excluded from the circulation but partially restored when neuropeptide Y (NPY) (1 nmol/kg i.v.) was administered. Radiolabeled microspheres were used to measure regional blood flow and from these measurements, regional vascular resistance was calculated. From these data, it is evident that ET-1 caused a generalized increase in vascular resistance, and only in the large intestine and epididymal fat pad was this attenuated by indomethacin. In the gastric vasculature, the effects of ET-1 were potentiated by indomethacin. In the bronchial vasculature, ET-1 caused a reduction in vascular resistance possibly due to the bronchoconstrictor actions of ET-1 and the concomitant release of vasodilators such as histamine. When the fraction of the cardiac output received by each vascular bed is taken into account, the gastrointestinal tract, kidneys, and skeletal muscle account for most of the increase in total peripheral resistance induced by ET-1. Prostanoids have a role in the pressor response to ET-1 and ET-3 that is more complex than one of simple physiological antagonism or potentiation at the level of the vascular smooth muscle and possibly act as modulators of other regulatory factors such as NPY.
在去大脑大鼠中研究了猪(ET-1)和大鼠(ET-3)内皮素的升压作用以及环氧化酶抑制剂对这些反应的影响。在内皮素给药前静脉注射吲哚美辛(15 μmol/kg)对ET-1或ET-3的升压反应无影响。然而,当在两剂ET-1或ET-3之间给予吲哚美辛或吡罗昔康时,第二次反应显著增强。当肾上腺被排除在循环之外时,这种增强作用消失,但当静脉注射神经肽Y(NPY)(1 nmol/kg)时部分恢复。使用放射性标记微球测量局部血流量,并根据这些测量结果计算局部血管阻力。从这些数据可以明显看出,ET-1导致血管阻力普遍增加,只有在大肠和附睾脂肪垫中,吲哚美辛可使其减弱。在胃血管系统中,吲哚美辛增强了ET-1的作用。在支气管血管系统中,ET-1导致血管阻力降低,这可能是由于ET-1的支气管收缩作用以及组胺等血管舒张剂的伴随释放。当考虑每个血管床接受的心输出量分数时,胃肠道、肾脏和骨骼肌占ET-1引起的总外周阻力增加的大部分。前列腺素在对ET-1和ET-3的升压反应中起作用,其作用比在血管平滑肌水平上简单的生理拮抗或增强作用更为复杂,并且可能作为其他调节因子(如NPY)的调节剂。